Open AccessBook
Chronic hepatitis B : an update
Naoky C. S. Tsai,Norman Gitlin +1 more
TLDR
A group of experts in this field is assembled to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice.Abstract:
A recent Institute of Medicine report has concluded that 'there is a lack of knowledge and awareness about chronic viral hepatitis on the part of health-care and social-service providers, as well as among at-risk populations, members of the public, and policy-makers. Due to the insufficient understanding about the extent and seriousness of this public-health problem, inadequate public resources are being allocated to prevention, control, and surveillance programs'. It is with these concerns in mind that Dr. Tsai assembled a group of experts in this field to present their expertise in such a level, where the practicing clinicians who deal with this disease in their daily practice can understand thereby implement this knowledge into their own practice. Dr. Brian McMahon discusses the natural history of chronic hepatitis B with his vast knowledge and experience working with the high endemic population of Inuit in Alaska. Drs. Marc Ghany and Ed provide a very easy-to-understand description of HBV virology. Dr. Kyon-Mi Chang contributes an article on HBV immunology, which is the least understood area of this disease but has the most potential to improve our knowledge in the management of chronic hepatitis B. Dr. Anna Lok provides an authoritative review on the current issues and controversies of treatment of chronic hepatitis B. Dr. Stephen Locarnini, who has extensive experience in anti-viral resistance and its management, presents important issues in the usage of currently available anti-viral oral agents. Dr. Myron Tong discusses the current understanding of HBV carcinogenesis and updates HCC surveillance and treatment - the most dreadful outcome of this disease. Dr. Paul Martin discusses management of end- stage chronic hepatitis B - anti-viral therapy, montherapy vs combo therapy, choice of agent, when to start therapy and post-transplant patients including duration of HBIG therapy, HBcAb(+)only recipient) and Occult HBV infection. Dr. Tram Tran discusses the treatment in reproductive women, during pregnancy, and prevention of vertical transmission in third trimester with antiviral agents - an area with significant lack of good clinical evidence. Dr. Steve Han discusses management of patients with acute hepatitis B, co-infection with HDV/HCV/HIV, pre-immuno-suppressive therapy, and management of renal and heart transplant patients with HBV infection. Dr. Mei Huei Chang discusses Taiwanese success in implementing universal vaccination leading to a remarkable reduction in both prevalence of chronic hepatitis B and incidence of hepatocellular carcinoma. Finally Drs. Michelle Lai and Yun Fan Liaw provide a rundown of what we have accomplished and the hope for the future in our fight to control this disease.read more
Citations
More filters
Journal ArticleDOI
Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog
Tai-Chung Tseng,Jia-Horng Kao +1 more
TL;DR: Taking these lines of evidence together, qHBsAg can complement HBV-DNA levels to optimize the management of CHB patients in the authors' daily clinical practice.
Journal ArticleDOI
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management
TL;DR: This paper reviews TNF mechanisms of action in viral hepatitis B and C, recommendations for managing HBV and HCV-infected patients receiving treatment with anti-TNF drugs, safety and anti- TNF hepatotoxicity, and expert opinion.
Journal ArticleDOI
Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement
TL;DR: The USPSTF concludes that persons at high risk for infection should be screened for HBV infection.
Journal ArticleDOI
Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B--a prospective cohort study with paired transient elastography examinations.
Grace Lai-Hung Wong,Hung Chan,Zhuo Yu,Anthony W.H. Chan,P. C.-L. Choi,Angel Mei-Ling Chim,Hoi-Yun Chan,Chi-Hang Tse,V. W.-S. Wong +8 more
TL;DR: Metabolic syndrome is a known risk factor of cirrhosis in chronic hepatitis B (CHB) and may be a cause of disease progression in patients with these conditions.
Journal ArticleDOI
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel
Vito Di Marco,Marcello Capra,Emanuele Angelucci,Caterina Borgna-Pignatti,Paul Telfer,Paul Harmatz,Antonis Kattamis,Luciano Prossamariti,Aldo Filosa,Deborah Rund,Maria Rita Gamberini,Paolo Cianciulli,Marianne de Montalembert,Francesco Gagliardotto,Graham R. Foster,Jean Didier Grangè,Filippo Cassarà,Angela Iacono,Maria Domenica Cappellini,Gary M. Brittenham,Daniele Prati,Antonello Pietrangelo,Antonio Craxì,Aurelio Maggio,Haemoglobinopathies +24 more
TL;DR: The knowledge on the epidemiology and the risks of transmission of viral infections are summarized, invasive and noninvasive methods for the diagnosis of chronic liver disease are analyzed, and the knowledge on clinical course of chronic viral hepatitis is reported.